Background: To estimate safety and efficacy of radical parametrectomy (RP) and radiation therapy (RT) or concurrent chemoradiation therapy (CCRT) for patients with occult invasive cervical cancer found after simple hysterectomy.
introduction
Cervical cancer is the second most common female cancer and one of the leading causes of cancer deaths in females worldwide [1, 2] . Widespread screening for cervical cancer has increased the rate of early-stage diagnosis. Most patients with early-stage cervical cancer undergo radical hysterectomy with pelvic 6 paraaortic lymphadenectomy, with 5-year survival rates of 75%-90% [3] [4] [5] . Sometimes, however, this malignancy is encountered after simple hysterectomy carried out for benign gynecologic conditions or preinvasive cervical lesions. Radical parametrectomy (RP), consisting of resection of the parametrium, upper vaginectomy, and pelvic 6 paraaortic lymphadenectomy may be carried out as a definite treatment in these patients [6, 7] . However, due to technical difficulties in carrying out RP and a lack of knowledge about the safety and efficacy of this operation, physicians tend to administer radiation therapy (RT) or concurrent chemoradiation therapy (CCRT) instead.
The aims of this study were to estimate the feasibility, safety, and efficacy of RP for occult invasive cervical cancer detected after simple hysterectomy carried out for benign gynecologic conditions or preinvasive cervical lesions and to compare the outcomes of patients who underwent RP with those who received RT or CCRT.
materials and methods
Following approval by the Institutional Review Board of the Asan Medical Center (AMC, Seoul, Korea), we searched the cancer registry and computerized database to identify patients with occult invasive cervical cancer detected after simple hysterectomy carried out for benign gynecologic conditions or preinvasive cervical lesions from 1989 to 2009. Patients' medical records were retrospectively reviewed, and demographic data including age, menopausal status, parity, and body mass index were recorded. We also reviewed patient's medical records for a history of cancer, other medical diseases, and surgery or RT of the pelvis. Clinical data included indication for hysterectomy; results of Papanicolaou smears taken before hysterectomy; presence of residual tumor; histologic type, size, and grade of each tumor; presence of lymphovascular space invasion (LVSI) in the hysterectomy specimen; presumed stage of disease, as determined using the International Federation of Gynecology and Obstetrics (FIGO) system for cervical cancer; the outcomes of diagnostic procedures; type and outcomes of definitive treatment after hysterectomy; lymph node (LN) status after RP; adjuvant therapy after RP; recurrence; and treatment at recurrence and death. Pathology slides were reviewed by two experienced pathologists and clinicopathological prognostic factors and treatment outcomes were analyzed.
surgical procedure for RP RP surgery was carried out through a midline laparotomy in 25 patients and through laparoscopic surgery using four trocars in 4 patients. Both surgical approaches were basically the same with type III hysterectomy [8] . Briefly, each surgical procedure commenced with a systemic bilateral pelvic 6 paraaortic lymphadenectomy. The ureters were dissected from the uterine artery and the cardinal ligaments and ureters were separated as much as possible from the bladder. Cardinal ligaments were severed at their most lateral portions and freed as much as possible from the surrounding tissue. The uterosacral ligaments were severed near the sacrum, and the paracolpium was resected as much as possible. An incision was made in the vaginal cuff at least 3-4 cm below the fornices.
statistical analysis
Frequency distributions were compared using the chi-square and Fisher's exact tests, and mean and median values were compared between the groups using the Student's t-test and the Mann-Whitney U test. Overall survival (OS) was calculated as the number of months from the date of simple hysterectomy to the date of death or the date censored. Disease-free survival (DFS) was calculated as the number of months from the date of simple hysterectomy to the date of recurrence or the date censored. Survival curves and rates were calculated using the Kaplan-Meier method. Differences in survival were assessed using the log-rank test for categorical factors and Cox proportional hazards model for continuous factors in univariate analysis. A P value of <0.05 in a two-sided test indicated a significant difference. Data were analyzed using SPSS software for Windows (version 11.0; SPSS Inc., Chicago, IL).
results
Of 2792 patients with invasive cervical cancer who were treated and followed at AMC during the study period, 147 (5.3%) had occult invasive cervical cancer found after simple hysterectomy carried out for benign gynecologic conditions or preinvasive cervical lesions. Of these 147 patients, 37 (25.2%) had undergone simple hysterectomy at other hospitals and 110 (74.8%) had undergone simple hysterectomy at AMC. The indications for simple hysterectomy included squamous intraepithelial neoplasia (CIN), including carcinoma in situ (CIS), in 102 patients (69.4%), leiomyoma in 32 patients (21.8%), adenomyosis in 4 patients (2.7%), adenocarcinoma in situ in 4 patients (2.7%), uterine prolapse in 3 patients (2.0%), intractable dysfunctional uterine bleeding in 1 patient (0.7%), and severe postpartum hemorrhage in 1 patient (0.7%). Of 102 patients who underwent inadvertent simple hysterectomy for CIN or CIS, 31 did so due to the failure to carry out conization or endocervical curettage and 71 did so due to the absence of invasive lesions in conization specimens. Of the remaining 45 patients who underwent inadvertent simple hysterectomy due to other benign gynecologic problems, 35 did so due to false-negative cytology and 10 did so due to the absence of cytologic evaluation before hysterectomy. Ninetyfive patients (64.6%) underwent total abdominal hysterectomy, 47 (32.0%) underwent laparoscopic-assisted vaginal hysterectomy, and 5 (3.4%) underwent vaginal hysterectomy. Sixty-five patients underwent unilateral (n = 11) or bilateral (n = 51) salpingo-oophorectomy or ovarian cystectomy (n = 3) during hysterectomy. After simple hysterectomy, presumed FIGO stage was IA1 in 48 patients (32.7%), IA2 in 7 patients (4.8%), IB1 in 85 patients (57.8%), IB2 in 4 patients (2.7%), and IIA in 3 patients (2.0%). The characteristics of the 147 patients are shown in Table 1 .
patients with IA1 lesions
The hysterectomy specimens from all 48 patients with IA1 lesions had negative resection margins. All patients had squamous lesions. After simple hysterectomy, none underwent further imaging. Six patients (12.5%) had positive LVSI. None of these patients underwent further treatment after simple hysterectomy. After a median follow-up time of 158 months (range 34-235 months), none of these patients had recurrent disease ( Figure 1 ).
patients with IA2-IIA lesions
Of the 99 patients with IA2-IIA lesions, 26 received no further definitive treatment, including RT, CCRT, or RP (observation/ chemotherapy group), and 44 patients received RT or CCRT (RT/CCRT group) and 29 underwent RP (RP group) as definitive treatments after simple hysterectomy.
observation/chemotherapy group. Of the 26 patients who did not receive RT, CCRT, or RP, 20 refused further treatment, whereas 6 received adjuvant chemotherapy; two patients received paclitaxel/cisplatin, three received 5-fluorouracil/cisplatin, and one received vincristine/ifosfamide/cisplatin. The mean number of chemotherapy cycles was 4 (range 3-6). All six patients who received adjuvant chemotherapy had IB1 lesions; of these, three had squamous cell carcinoma and three had adenocarcinoma. Of the 26 patients in this group, 2 underwent computed tomography (CT) of the abdomen and pelvis, 3 underwent magnetic resonance imaging (MRI) of the abdomen and pelvis, and 2 underwent whole-body positron emission tomography-computed tomography (PET-CT) after simple hysterectomy. None showed evidence of a pelvic lesion or lymphadenopathy. After a median follow-up time of 104 months (range 7-232 months), nine patients (34.6%) had recurrent disease. The median time to recurrence was 46 months (range 4-137 months). Recurrent sites were the vaginal stump (n = 2), the pelvis (n = 4), the pelvis and pelvic LNs (n = 1), and the pelvis and paraaortic LNs (n = 2). Four patients received RT and five patients received CCRT at recurrence, with four dying of disease. The 10-year DFS and OS rates were 63% and 84%, respectively ( Figure 1 ). Of the six patients who received adjuvant chemotherapy, one (17%) had recurrent disease and died of disease. Of the remaining 20 patients who did not receive adjuvant chemotherapy, 8 (40%) had recurrent disease and 3 (15%) died of disease. There were no differences in DFS and OS between the two groups (P = 0.315 and 0.935, respectively). cisplatin in one patient, paclitaxel/cisplatin in two patients, and 5-fluorouracil/cisplatin in nine patients. The mean number of chemotherapy cycles was 3.3 (range 1-6). The mean time from hysterectomy to the commencement of RT or CCRT was 29 days (range 8-124 days). Twenty-three patients received wholepelvic radiation therapy (WPRT) only, 3 patients received intracavitary radiation therapy (ICR) only, and 18 patients received both. The mean radiation dose for WPRT was 5006 cGy (range 4000-5080 cGy), and the mean radiation dose for ICR was 2162 cGy (range 1500-3000 cGy). The mean duration of RT or CCRT was 49 days (range 13-67 days). In four patients, RT or CCRT was delayed due to severe diarrhea. RT or CCRT were well tolerated in other patients. Of the 44 patients in this group, 7 underwent CT, 12 underwent MRI, and 2 underwent PET-CT after simple hysterectomy. Only two MRI scans revealed suspected residual tumors in the vaginal stump. After a median follow-up time of 116 months (range 9-232 months), three patients (6.8%) had recurrent disease. The median time to recurrence was 9 months (range 6-19 months). Recurrent sites were the pelvis in one patient; the pelvis, paraaortic, and cervical LNs in one patient; and bone and lung in one patient. One patient received chemotherapy consisting of three cycles of paclitaxel/cisplatin, and two patients received CCRT (one received three cycles of paclitaxel/cisplatin and the other received three cycles of 5-fluorouracil/cisplatin); of these three patients, two died of disease. The characteristics of the three patients who had recurrent disease after RT or CCRT are shown in Table 2 . The 10-year DFS and OS rates were 93% and 94%, respectively ( Figure 1 ). During follow-up after RT or CCRT, 12 patients (27%) suffered late complications related to RT requiring further management; these complications included radiation cystitis (n = 4), radiation proctitis or colitis (n = 6), radiation vaginitis (n = 4), rectovaginal fistula (n = 1), and ureteral stricture (n = 1). Two patients required surgical management.
Of the 12 patients with late complications, 8 (67%) had received WPRT and ICR, with a total dose of >6540 cGy, and 4 (33%) had received WPRT only, with a total dose of 5040 cGy. Of the 44 patients who received RT or CCRT, four had positive resection margins on simple hysterectomy specimens. Of these, three patients with FIGO stage IB1 lesions received RT, one patient with a FIGO stage IB2 lesion received CCRT with three cycles of 5-fluorouracil and cisplatin, and one patient with a FIGO stage 1B1 lesion underwent RP. None showed evidence of recurrent disease after treatment.
RP group. Twenty-nine patients underwent RP with pelvic lymphadenectomy. Nineteen patients underwent paraaortic lymphadenectomy, 11 underwent unilateral or bilateral salpingo-oophorectomy, and 3 underwent ovarian transposition during RP. Four patients underwent laparoscopic RP. Of the 29 patients who underwent RP, one patient with a IB1 lesion had positive resection margins on simple hysterectomy specimen. One patient underwent CT, 10 underwent MRI, and 7 underwent PET-CT after simple hysterectomy. Only one MRI scan revealed a residual tumor in the vaginal stump. The mean time from simple hysterectomy to RP was 34 days (range 13-114 days). The mean operating time was 297 min (range 172-433 min), and the mean estimated blood loss during surgery was 538 ml (range 200-1000 ml). Seventeen patients (59%) required perioperative transfusions, with a mean transfusion volume of 2.4 pints (range 1-5 pints). The mean preoperative and postoperative hemoglobin (Hb) concentrations and perioperative Hb change were 13.1 gm/dl (range 11.9-14.3), 11.0 gm/dl (range 9.1-13.6), and 2.1 gm/dl (range 0.5-5.6), respectively. Three intraoperative complications were recorded, including one bladder perforation and two rectal serosa lacerations, all of which were managed with intraoperative suturing. After surgery, two patients experienced complications, including one with mechanical ileus that was managed conservatively and one with urethrocutaneous fistula that was managed surgically. The mean time to return of bowel movements was 2.8 days (range 1.0-4.0 days). The mean postoperative hospital stay was 17 days (range 7-43 days). In three patients, residual disease was found on the vaginal stump after RP, measuring 0.4, 0.5, and 0.5 cm, respectively. No RP specimen showed involvement of the parametrium or resection margin. The mean number of total, paraaortic, and pelvic LNs retrieved were 36.8 (range 13-57), 4.3 (range 3-7), and 33.4 (13-53), respectively. Four patients had LN metastasis; the mean number of LNs involved was 1.8 (range 1-3). Two patients had right obturator LN metastasis, one had right internal iliac LN metastasis, and one had involvement of both external iliac LNs. The characteristics of the four patients with LN metastasis are shown in Table 3 . Four patients with LN metastasis and one with two intermediate risk factors (positive LVSI and stromal invasion >2/3) received adjuvant therapy after RP; one received RT, one received five cycles of paclitaxel/cisplatin, one received three cycles of 5-fluorouracil/cisplatin, and two received CCRT, consisting of three cycles of 5-fluorouracil/cisplatin or six cycles of weekly cisplatin. After a median follow-up of 73 months (range 3-220 months), no patient showed evidence of disease recurrence (Figure 1 ) or late complications related to RP that required further management.
discussion
Our findings indicate that occult IA1 cervical cancer found after simple hysterectomy can be followed safely without further management, regardless of the status of LVSI. In patients with Annals of Oncology original article RT, radiation therapy; CCRT, concurrent chemoradiation therapy; FIGO, International Federation of Gynecology and Obstetrics; LVSI, lymphovascular space invasion; DSI, depth of cervical stromal invasion; RM, resection margin on simple hysterectomy specimen; RFS, recurrence-free survival; OS, overall survival; SCCa, squamous cell carcinoma; wP, weekly cisplatin; WPRT, whole-pelvic radiation therapy; ICR, intracavitary radiation therapy; DOD, die of disease; FP, 5-fluorouracil + cisplatin; AWD, alive with disease. LN, lymph node; RP, radical parametrectomy; FIGO, International Federation of Gynecology and Obstetrics; LVSI, lymphovascular space invasion; DSI, depth of cervical stromal invasion; RM, resection margin on simple hysterectomy specimen; OS, overall survival; AdCa, adenocarcinoma; CCRT, concurrent chemoradiation therapy; FP, 5-fluorouracil + cisplatin; NED, no evidence of disease; SCCa, squamous cell carcinoma; wP, weekly cisplatin; TP, paclitaxel + cisplatin; RT, radiation therapy.
original article Annals of Oncology more advanced early-stage lesions (stage IA2-IIA), however, a definitive treatment, such as RT, CCRT, or RP, is necessary because these patients are at increased risk of recurrence and death, although they received adjuvant chemotherapy after simple hysterectomy. Although similar survival outcomes were obtained in the RT/CCRT and RP groups, the lower rate of late complications after RP makes the latter preferable compared with RT/CCRT in this patient population. RP was feasible in all patients in our series and the operative parameters and complications were acceptable. Cervical cancer may be found incidentally after simple hysterectomy carried out for benign gynecologic conditions or preinvasive cervical lesions. The incidence of occult invasive cervical cancer, however, is not clear, although in the present study it comprised 5.3% of all cervical cancers. Occult invasive cervical cancer after simple hysterectomy can occur due to several causes. We found that the absence of invasive lesions in the conization specimens from patients with CIN or CIS and falsenegative cytology were the most common causes of inadvertent simple hysterectomy. Other studies have found that the most common causes of inadvertent simple hysterectomy were the lack of preoperative Pap smear, negative cytology, and no clinical evidence of cancer, followed by inadequate evaluation of an abnormal Pap smear or cervical biopsy and failure to carry out conization or endocervical curettage [7, 9, 10] .
If a lesion is found to be IA1 cervical cancer, further management is not required, regardless of the status of LVSI [11, 12] . However, if the lesion is larger, definitive RT, CCRT, or RP is required because higher recurrence and death rates have been observed in patients who did not receive further management or who received adjuvant chemotherapy only. Although we found that patients who did not receive definitive treatment had smaller tumors and a greater incidence of superficial (<1/3) stromal invasion than those in the RT/CCRT and RP groups, 34.6% of patients had recurrent disease. All of these patients had pelvic failure and some also had distant failure. Using RT or CCRT for recurrent disease, five patients were successfully re-treated, but four patients died of disease. These results are in agreement with previous findings indicating that simple hysterectomy is not sufficient for patients with more than microinvasive cervical carcinoma (stage IA1 disease) due to high recurrence and mediocre survival rates [13] [14] [15] .
Five-year survival rates after RT for occult cervical cancer have been found to range from 54% to 93% [9, [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] (Table 4 ). In our series, 10-year DFS and OS rates after RT or CCRT were 93% and 94%, respectively. Factors associated with poor outcome after RT or CCRT may include residual disease after simple hysterectomy [17, 18, 21, 24] , positive resection margins in hysterectomy specimens [18] , deeper cervical stromal invasion [3, 20] , long time interval from hysterectomy to RT (>6 months) due to delayed RT [18, 27] , and histologic type of adenocarcinoma [3] .
In general, late complications of RT for cervical cancer have been reported in 5%-15% of patients [28] . Most early studies, however, included relatively short follow-up periods. In more recent studies, with longer follow-up, significant late complication rates of 10%-16% [29, 30] and 16%-21% have been reported [31] . In our series, late complications were observed in 27% of patients after a median follow-up of 100 months. Surgical intervention was required in 4.5% of patients, similar to previously reported rates of 6%-7% [3, 21, 24] . In agreement with previous results, most of our patients with late complications received WPRT and ICR, with total dose >6540 cGy [3, 21, 24] . Although the role of brachytherapy in combination with WPRT is not yet clear, most patients treated with WPRT alone in our series did well. Considering the higher rate of complications, ICR may be safely omitted in selected patients.
Five-year survival rates after RP have been reported to range from 67% to 96% [6, 7, [32] [33] [34] [35] (Table 4) . We observed 10-year DFS and OS rates after RP of 100%, providing further evidence of the safety of RP in patients with: (i) FIGO stage IA2-IIA tumors; (ii) squamous cell carcinoma, adenocarcinoma, or adenosquamous cell carcinoma; and (iii) tumors <4 cm in diameter, regardless of grade of tumor, depth of invasion, or LVSI. Although previous studies have indicated that all patients with positive surgical margins on simple hysterectomy specimens are poor candidates for RP [6] , our results indicate that if there is no parametrial involvement, RP can be carried out safely in patients with small residual disease on the vaginal stump after simple hysterectomy. However, if there is a high probability that a patient will receive adjuvant RT or CCRT after RP, then RT or CCRT should be carried out instead of RP because the combination of radical surgery and RT is associated with a particularly high morbidity rate with no further survival benefit [5] . Indeed, large prospective trials are required to fully establish the patient eligibility criteria for RP. Most physicians are reluctant to carry out RP in patients with IA2-IIA occult invasive cervical cancer because they consider the RP procedure to be quite difficult, require an experienced surgeon, and be associated with a high rate of surgery-related morbidity. Therefore, most patients with IA2-IIA occult invasive cervical cancer undergo RT or CCRT [9, [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] , with few undergoing RP [6, 7, [32] [33] [34] [35] . This is in contrast to the current treatment of patients with early-stage cervical cancer, most of whom undergo radical hysterectomy as primary treatment. RP has been found to be feasible for most patients and not particularly technically difficult, as assessed by objective measures such as operating time, estimated blood loss, transfusion requirement, and postoperative hospital stay [6, 7, [32] [33] [34] [35] . We found that the perioperative complication rate was 17%, which is within the previously reported range of 8.7%-30% [6, 7, [32] [33] [34] [35] . In the present study, most complications were easily managed, either intraoperatively or conservatively. The occurrence of long-term morbidity after RP is rare.
In conclusion, we have shown that the survival outcome after RP was similar to that after RT or CCRT in patient populations with similar disease stage, tumor size, positive resection margin, positive LVSI, grade of tumor, and depth of stromal invasion. In addition, RP was feasible in all patients. The immediate surgical parameters were acceptable, the rate of perioperative complications was very low, and there was no late morbidity. Due to the high rates of long-term morbidity after RT or CCRT, RP may be preferable for selected patients with IA2-IIA occult invasive cervical cancer. We think that RP may be of greatest benefit in young patients who want to preserve their ovarian and sexual function. 
